Cambridge Clinical Laboratories (CCL) announces today, Friday 27 August, that CCL will be the UK partner for Prostatype Genomics in bringing the Prostatype® prostate cancer gene test to the UK market. 

CCL will now offer the Prostatype® prostate cancer gene test in its own labs, as well as promoting the test to uro-oncological facilities all over UK and Ireland.

Prostatype®'s unique system identifies the genetic fingerprint of cancer by measuring information from cancer stem cell genes. The gene expressions together with other clinical parameters such as PSA, Gleason and Tumor stage are entered into the Classification of Prostatic Malignancy Algorithm (CPMA) software that is linked to a unique patient data base. The software calculates the so-called P-score that provides a measure of how aggressive the cancer is, which facilitates the choice of optimal treatment for the patient.

Dr Anthony Cooke, CEO of CCL, said: “The Prostatype® test, identifying the genetic fingerprint of cancer, is exactly the kind of smart and innovative solution we want to introduce, implement and drive.”

Prostatype Genomics CEO, Fredrik Persson, comments: “We are very happy to be working together with Cambridge Clinical Laboratories, they have an impressive reputation for constantly pushing the envelope when it comes to finding new technologies and smart solutions that create value for healthcare and help patients. Stepping into these new and exciting markets, this agreement will be key.”

Press contact: Kelly Morel, PR Manager, kelly@happycommunications.co.uk